The trial included 648 patients aged 30 to 80 years with early-stage Parkinson’s disease. Credit: R Photography Background / ...
Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...
Feb 6 (Reuters) - Biogen forecast annual profit above Wall Street estimates on Friday, banking on demand for newer medicines and strength of its promising late-stage pipeline to return to revenue ...
Biogen axed an Ionis-partnered antisense oligonucleotide that targets LRRK2 last year. Other biotechs continue to work on the ...
MarketBeat on MSN
Biogen stock slides after trial miss, but analysts stay bullish
Key Points Interested in Biogen Inc.? Here are five stocks we like better. Biogen's diranersen missed its primary endpoint in ...
Zacks Investment Research on MSN
Denali stock dips as Biogen-partnered Parkinson's disease study fails
Shares of Denali Therapeutics, Inc. DNLI were down 8% in after-market trading on May 21, after the company and partner Biogen ...
Biogen and Denali have now confirmed that the results show BIIB122 (also known as DNL151) did not slow the progression of ...
High level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running ...
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the ...
Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest ...
Biogen (BIIB) stock and Denali Therapeutics (DNLI) stock drop after the companies decide to halt development of a Parkinson’s ...
Biogen’s Apellis acquisition consolidates a complement franchise spanning retinal and renal indications, with near-term label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results